<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05120297</url>
  </required_header>
  <id_info>
    <org_study_id>AK101-302</org_study_id>
    <nct_id>NCT05120297</nct_id>
  </id_info>
  <brief_title>A Phase 3 Study of Efficacy and Safety of AK101 in Subjects With Psoriasis</brief_title>
  <official_title>A Study to Evaluate the Efficacy and Safety of AK101 in Subjects With Moderate-to-severe Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Akeso</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Akeso</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, multicentered phase III clinical&#xD;
      study to evaluate the efficacy and safety of AK101 in the treatment of subjects with&#xD;
      moderate-to-severe plaque psoriasis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, multicenter phase III clinical study.&#xD;
      The purpose of this study is to evaluate the efficacy and safety of AK101 in the treatment of&#xD;
      subjects with moderate-to- severe plaque psoriasis. Subjects will be randomized to receive&#xD;
      AK101 or placebo injection subcutaneously, and follow up to week 16.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 1, 2021</start_date>
  <completion_date type="Anticipated">February 17, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 17, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subjects who achieved at least 75% (PASI 75) reduction in psoriasis area and severity index (PASI) score from baseline.</measure>
    <time_frame>At week 16</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects who achieved static physician global assessment (sPGA) clearance or very slight (0/1).</measure>
    <time_frame>At week 16</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects who achieved at least 50% (PASI 50), 75% (PASI75, except week 16) and 90% (PASI 90) reduction in PASI score at each visit.</measure>
    <time_frame>Baseline to week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects who achieved sPGA 0/1 at each visit.</measure>
    <time_frame>Baseline to week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change of PASI from baseline.</measure>
    <time_frame>Baseline to week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: AK101 serum concentration at different time points after administration.</measure>
    <time_frame>Baseline to week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity assessment: number and percentage of subjects with detectable anti-AK101 antibody (ADA).</measure>
    <time_frame>Baseline to week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAE).</measure>
    <time_frame>Baseline to week 16</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Psoriasis Vulgaris</condition>
  <arm_group>
    <arm_group_label>AK101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AK101</intervention_name>
    <description>Subjects will receive AK101 subcutaneous injection at week 0 and week 4, and will follow up to week 16.</description>
    <arm_group_label>AK101</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects will receive placebo subcutaneous injection at week 0 and week 4, and will follow up to week 16.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female subjects aged ≥ 18 years.&#xD;
&#xD;
          2. Subjects diagnosed with moderate-to-severe plaque psoriasis for at least 6 months&#xD;
             before screening.&#xD;
&#xD;
          3. At screening and baseline, PASI score ≥ 12, Body Surface Area BSA (BSA) ≥ 10%, sPGA ≥&#xD;
             3.&#xD;
&#xD;
          4. Subjects with a history of an inadequate response, intolerable or medically&#xD;
             inappropriate use of systemic therapy and/or phototherapy.&#xD;
&#xD;
          5. Subjects who are women of childbearing potential must have a negative pregnancy test&#xD;
             at screening and must be practicing an adequate, medically acceptable method of birth&#xD;
             control for at least 6 months after the last study drug administration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Forms of psoriasis other than chronic plaque-type psoriasis.&#xD;
&#xD;
          2. History or evidence of active TB. Patients with evidence of latent tuberculosis may&#xD;
             enter the trial after sufficient treatment had initiated and maintained according to&#xD;
             protocol.&#xD;
&#xD;
          3. Positive results of confirmatory test for hepatitis B, hepatitis C, human&#xD;
             immunodeficiency virus (HIV) or syphilis.&#xD;
&#xD;
          4. History of repeated chronic infection, had any serious infection or systemic infection&#xD;
             within 2 months before screening.&#xD;
&#xD;
          5. History of prohibited psoriasis treatments within 2/4 weeks before randomization.&#xD;
&#xD;
          6. History of IL12/23 or IL-23 inhibitors therapy.&#xD;
&#xD;
          7. Inadequate washout period of prior biological therapy.&#xD;
&#xD;
          8. History of malignant tumour within 5 years before screening.&#xD;
&#xD;
          9. Any medical or psychiatric condition, laboratory, or ECG parameter which, in the&#xD;
             opinion of the Investigator would place the subject at risk, interfere with&#xD;
             participation or interpretation of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 1010</name>
      <address>
        <city>Bengbu</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 1028</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 1013</name>
      <address>
        <city>Wuhu</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 1001</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 1027</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 1034</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 1035</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 1036</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 1049</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 1051</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 1041</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 1007</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 1021</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 1024</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 1018</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 1023</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 1030</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 1012</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 1039</name>
      <address>
        <city>Guiyang</city>
        <state>Guizhou</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 1025</name>
      <address>
        <city>Chengde</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 1017</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 1031</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 1014</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 1033</name>
      <address>
        <city>Nanyang</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 1045</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 1004</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 1006</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 1026</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 1052</name>
      <address>
        <city>Lianyungang</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 1029</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 1009</name>
      <address>
        <city>Xuzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 1015</name>
      <address>
        <city>Yancheng</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 1019</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 1020</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 1032</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 1047</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 1008</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 1048</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 1050</name>
      <address>
        <city>Hohhot</city>
        <state>Neimenggu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 1044</name>
      <address>
        <city>Yinchuan</city>
        <state>Ningxia</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 1038</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 1042</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 1043</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 1005</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 1046</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 1011</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 1016</name>
      <address>
        <city>Suining</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 1040</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 1037</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 1002</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 1003</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 1022</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 3, 2021</study_first_submitted>
  <study_first_submitted_qc>November 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

